Clinical trial NCT00003172 (phase 2, status: completed)
Conditions: gastric cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: docetaxel, doxorubicin hydrochloride, fluorouracil, hydroxyurea
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, NC(=O)NO
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the stomach or
        gastroesophageal junction beyond the scope of surgical resection Must have measurable
        disease in either one or two dimensions either radiographically or by physical examination
        Measurable disease must be documented outside of a prior radiation portal Evaluable disease
        only not allowed

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy: Not
        specified Hematopoietic: WBC greater than 4,000/mm3 Absolute neutrophil count greater than
        1,500/mm3 Platelet count greater than 100,000/mm3 Hepatic: Bilirubin no greater than upper
        limit of normal (ULN) SGOT no greater than 1.5 times ULN Alkaline phosphatase no greater
        than 5 times ULN Renal: Creatinine less than 2.0 mg/dL Cardiovascular: No New York Heart
        Association class III or IV heart disease No chronic or unstable angina No uncontrolled
        congestive heart failure No arrhythmia No chronic angina No myocardial infarction in the
        past 1 year If history of atherosclerotic heart disease, prior cardiac catheterization or
        thallium stress test must not suggest coronary artery disease Neurology: No symptomatic
        peripheral neuropathy greater than grade 2 No cerebellar disease No seizure disorder No
        organic mental syndrome No major psychoaffective disorder Pulmonary: No chronic obstructive
        pulmonary disease No chronic bronchitis, emphysema, sarcoid, or bronchiectasis Other: No
        poorly controlled diabetes mellitus No psychiatric illness No active infections, including
        AIDS, ARC, or HIV positive No history of hypersensitivity to products containing
        Polysorbate 80 No history of uncontrolled alcohol or drug abuse No uncontrolled
        hypercalcemia No other prior malignancy within the past 5 years other than nonmelanomatous
        skin cancer or cervical carcinoma in situ Not pregnant or nursing Adequate contraception
        required of all fertile patients

        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunotherapy Chemotherapy: No
        prior systemic chemotherapy Endocrine therapy: No chronic use of steroids No concurrent
        hormonal therapy (except birth control pills) Radiotherapy: At least 1 month since prior
        radiotherapy No concurrent palliative radiotherapy (arm I patients) Surgery: Must have
        fully recovered from surgery Other: At least 4 weeks since other investigational agents and
        recovered from all toxic effects No chronic use of aspirin, nonsteroidal antiinflammatory
        agents, antianginal medications, or extraordinary antihypertensive regimens